Lylly's Actos outruns Avandia sales due to drug safety problems.

Published: 2007-08-27 06:57:00

Updated: 2007-08-27 06:57:00

The sales of Actos, a rival anti-diabetic drug for type 2 diabetes developed and marketed by Lilly, showed far surpassing to Avandia by 24% increase in June over the previous month probably due to the recent serious reports on the increased risk of cardiovascular disease on the New England Journa...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK